ABVC BioPharma Reveals Receipt Of $200K Cash Payment From OncoX BioPharma As Part Of Its Strategic Licensing Agreement For Certain Oncology-related Products
ABVC BioPharma Reveals Receipt Of $200K Cash Payment From OncoX BioPharma As Part Of Its Strategic Licensing Agreement For Certain Oncology-related Products
ABVC生物製藥公司透露，收到OncoX生物製藥公司200,000美元的現金付款，作爲其某些腫瘤相關產品戰略許可協議的一部分。
This payment marks the first installment of $5 million in potential licensing fees from OncoX.
這筆支付標誌着從OncoX獲得潛在許可費的第一期500萬美元。
With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.
通過這筆支付，ABVC從其三家戰略合作伙伴那裏獲得的各種ABVC產品的累計現金支付總額爲546,000美元。ABVC及其子公司BioLite Inc.和Rgene Corporation都有資格在產品推出後各自獲得最多1000萬OncoX股票、500萬美元現金支付以及最高5000萬美元的特許權使用費。
資訊熱榜
更新時間